Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
NCT05786040Phase 2Recruiting
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in Post-Transplant Lymphoproliferative Disorder (PTLD). Started Mar 2023; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT05786040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786040.